Table 1.
List of clinical trials using OVs in combination with immunomodulatory strategies for various cancers.
| Trial | Virus Type | OV Agent | Immunomodulatory Therapy | Phase (s) | Cancer (s) | |
|---|---|---|---|---|---|---|
| Agent | Description | |||||
| NCT03747744 | HSV | T-Vec | CD1c (BDCA-1)+ myDC | CD1c+ myeloid dendritic cells | I | Melanoma |
| NCT02197169 | Adenovirus | DNX-2401 | IFNγ | Pro-inflammatory | I | Glioblastoma or Gliosarcoma |
| NCT02143804 | Adenovirus | CG0070 | GM-CSF (encoded) | M1 polarizer | II | Bladder Cancer, High Grade, Non-Muscle Invasive |
| NCT00625456 | Vaccinia | RACVAC (JX-594) | GM-CSF (encoded) | M1 polarizer | I | Melanoma, Lung Cancer Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Neuroblastoma |
| NCT01169584 | Vaccinia | RACVAC (JX-594) | GM-CSF (encoded) | M1 polarizer | I | Rhabdomyosarcoma, Lymphoma Wilm’s Tumor, Ewing’s Sarcoma |
| NCT04725331 | Vaccinia | BT-001 | Anti CTLA-4 mAb (encoded) | ICB | I, II | Solid Tumor, Adult Metastatic Cancer Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer Non-Small Cell Lung Cancer |
| NCT04050436 | HSV | RP1 | GM-CSF (encoded) | M1 polarizer | II | Squamous Cell Carcinoma |
| Cemiplimab (combination) | PD-1 | |||||
| NCT03767348 | HSV | RP1 | GM-CSF (encoded) | M1 polarizer | II | Melanoma, NSCLC |
| Nivolumab (combination) | PD-1 | II | ||||
| NCT00554372 | Vaccinia | JX-594 | GM-CSF (encoded) | M1 polarizer | II | Hepatocellular Carcinoma |
| NCT00629759 | Vaccinia | JX-594 | GM-CSF (encoded) | M1 polarizer | I | Liver neoplasms |
| NCT04521764 | Measles | MV | NAP (encoded) | Secretes neutrophil activating protein | I | Breast cancer |